Abstract:David B Nelson, Yevgenia Y Fomina Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas, TX, USA Correspondence: David B Nelson, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, H6.106, Dallas, TX, 75235, USA, Email Preterm birth is the leading cause of infant morbidity and mortality in children younger than 5 years old and accounts for approximately 35% of newborn deaths worldwide. The use of progestogen therapy for prevention of preterm birth has been one of the most controversial topics in modern obstetrics. Progestogens can be classified as natural or synthetic. Progesterone is a natural progestogen while progestins such as 17-alpha-hydroxyprogesterone caproate (17OHP-C) are synthetic steroid hormones. Evidence supporting the use of progestogens varies by formulation and populations studied. After more than a decade, the US Food and Drug Administration has withdrawn accelerated approval of 17OHP-C for the prevention of recurrent preterm birth in pregnant individuals with a singleton gestation. With this decision, there is no current FDA-approved treatment for prevention of spontaneous preterm birth. In this review, we provide a historical context behind the rise and fall of 17OHP-C clinical application, highlight the challenges behind the data supporting progestogen use, and offer suggestions on how to make an impact on preterm birth moving forward. Keywords: accelerated approval, anxiety, FDA, healthcare costs, Makena ® , National Institute of Health, neonatal morbidity and mortality, pregnancy, preterm birth, progestin, progestogen, progesterone, spontaneous preterm birth, 17-alpha-hydroxyprogesterone caproate Preterm birth is defined by the World Health Organization (WHO) as delivery prior to 37 weeks of gestation based on the obstetric estimate. 1 In the United States (US), 66% of infant deaths in 2018 occurred in preterm infants, with the infant mortality rate at less than 28 weeks 186 times higher than at 37 to 41 weeks. 2,3 Infants born preterm with low-birthweight and survive have significantly higher risks of both short- and long-term morbidity and mortality. 4 The frequency of these tragedies is inversely related to gestational age. For example, the incidence of cerebral palsy for infants born prior to 28 weeks is 15% as compared to 0.13% at term. 5,6 Beyond the neonatal period, survivors of PTB also have increased risks of chronic diseases, such as elevated blood pressure, heart failure, chronic kidney disease, diabetes, and obstructive lung disease. 5 Large cohort studies report that patients born preterm have approximately 30% to 50% higher all-cause mortality between 18 and 45 years than those born full-term. 7 While early preterm births (<34 weeks) comprise the majority of severe neonatal complications, late preterm birth impacts a larger proportion of individuals and also carries neonatal risks. In a retrospective cohort study of 261,194 singletons born at 24 weeks or greater at Parkland Hospital, all measured adverse neonatal outcomes were significantly increased in the late preterm births as compared to "term" 39-week deliveries. The rate of aggregated morbidity was 34% of births at 34 weeks, as compared to 14% at 39 weeks. 8 Taken together, preterm birth translates to substantial healthcare expenditures. 9 The total societal burden of preterm birth was estimated at $25.2 billion based on the 2016 US birth cohort data. 10,11 Beyond financial costs, the emotional burden of preterm birth to patients, families, communities, and societies cannot be overstated. The rate of preterm birth in the US reached a nadir at 9.6% in 2014 but has been steadily rising since then to 10.5% in 2021 (Figure 1). The 2022 March of Dimes report card highlights the worsening state of maternal and infant health in the US and the increasing preterm birth rate. 12 More than 70% of preterm births occur between 34 and 36 weeks of gestation. The recent increase in the overall preterm birth rate is largely driven by these late preterm deliveries that rose by an average annual rate of 2% from 2014 to 2019. 13 The rate of early preterm birth, defined as births before 34 weeks of gestation, has remained unchanged at 2.8% since 2014. 1 Figure 1 Preterm birth rate in the United States over time. Adapted from March of Dimes full report card; 2022. Available from: https://www.marchofdimes.org/peristats/data?top=3&lev=1&stop=60®=99&obj=1&slev=1 . 12 Preterm birth is classified as spontaneous or medically initiated for maternal or fetal indications. It is e -Abstract Truncated-

Global burden of preterm birth

Preterm Birth, Exasperation to the South Asian Countries

The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity

The global burden of disease attributable to preterm birth and low birth weight in 204 countries and territories from 1990 to 2019: An analysis of the Global Burden of Disease Study

National, Regional, and Global Estimates of Preterm Birth in 2020, With Trends From 2010: A Systematic Analysis

Preterm birth in low-middle income Countries

Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels.

Mortality risk in preterm and small-for-gestational-age infants in low-income and middle-income countries: a pooled country analysis

A Trend Study of Preterm Infant Mortality Rate in Developed and Developing Countries over 1990 to 2017

Global, Regional, and National Incidence and Mortality of Neonatal Preterm Birth, 1990-2019

The global epidemiology of preterm birth

Stillbirths: rates, risk factors, and acceleration towards 2030

Epidemiology of late preterm and early term births - An international perspective

Estimates of neonatal morbidities and disabilities at regional and global levels for 2010: introduction, methods overview, and relevant findings from the Global Burden of Disease study

National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010

The causes of preterm neonatal deaths in India and Pakistan (PURPOSe): a prospective cohort study

Cause-of-death estimates for the early and late neonatal periods for 194 countries from 2000-2013

Global, regional, and national progress towards Sustainable Development Goal 3.2 for neonatal and child health: all-cause and cause-specific mortality findings from the Global Burden of Disease Study 2019

Prevalence of Preterm Birth and Perinatal Outcomes in a Tertiary Hospital in Malaysia

Challenges in Using Progestin to Prevent Singleton Preterm Births: Current Knowledge and Clinical Advice

Magnitude of prematurity in the countries of the Great Maghreb